LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Clinical Laboratory Tests Market Driven by Demand for Molecular, Pathological and Immunological Testing

By LabMedica International staff writers
Posted on 17 Dec 2021
Print article
Illustration
Illustration

The global clinical laboratory tests market is expected to surpass USD 327 billion by 2028, driven by a growing geriatric population and increasing molecular, pathological, and immunological tests.

These are the latest findings of Reports and Data (New York City, NY, USA), a market research and consulting company.

Rising prevalence of chronic and acute diseases globally, growing geriatric populace worldwide, increasing health awareness among people, and escalating need for early and accurate disease diagnosis are key factors expected to propel market growth. In addition, rising prevalence of target diseases, such as tuberculosis and diabetes, and cardiovascular disorders, growing awareness about regular body profiling, and increasing demand for molecular, pathological, and immunological testing are expected to further stimulate revenue growth. Strict government norms regarding clinical laboratory testing are expected to create further opportunities for the growth of the global clinical laboratory tests market.

Clinical laboratory tests refer to various medical tests performed in a laboratory to gain information about the health condition of a patient by using their blood or urine samples. These tests aid in the accurate diagnosis and prognosis of patients’ medical condition. The principal areas of clinical laboratory testing include clinical microbiology, clinical chemistry, hematology, DNA testing, and reproductive biology tests. Some of the commonly used clinical laboratory tests are Complete Blood Count (CBC), comprehensive metabolic panel, basic metabolic panel, liver panel, lipid panel, HbA1c, HGB/HCT, urinalysis, and thyroid stimulating hormone. Increasing government and private investments to develop advanced laboratory testing procedures, rapid adoption of highly advanced clinical diagnostic techniques, and increasing patient-centric approaches toward management of chronic and viral diseases are other significant factors expected to drive market growth.

Based on test type, the basic metabolic tests segment is expected to hold the highest share of the global clinical laboratory tests market over the coming years, due to rising prevalence of lifestyle-induced diseases such as cardiovascular disorders and growing health awareness among people globally. Based on stand-alone laboratories, the service provider segment is expected to record the fastest revenue growth, driven by the rising prevalence of chronic and acute diseases, profoundly increasing patient pool, growing demand for technologically advanced laboratory equipment, and increasing need for rapid and accurate test results. Geographically, North America is expected to lead the global clinical laboratory tests market owing to its growing geriatric population, rising volumes of laboratory tests, and increasing adoption of state-of-the-art clinical diagnostic procedures. The North American clinical laboratory tests market is expected to gain further momentum in the coming years due to the rapidly advancing healthcare infrastructure in the region.

Related Links:
Reports and Data

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more